Home > Boards > US OTC > Medical - Drugs > Millendo Therapeutics, Inc. (MLND) (MLND)

Millendo Therapeutics to Participate in September Investor Conferences

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DMOST Member Profile
Member Level 
Followed By 69
Posts 5,554
Boards Moderated 1
Alias Born 10/19/06
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/5/2021 9:09:33 AM
Millendo Therapeutics Provides Pipeline and Business Update Business Wire - 1/5/2021 9:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 11/10/2020 7:49:46 AM
Millendo Therapeutics Reports Third Quarter 2020 Operating and Financial Results Business Wire - 11/9/2020 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/9/2020 7:02:31 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/24/2020 8:34:06 AM
Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist Business Wire - 9/24/2020 8:30:00 AM
Millendo Therapeutics to Participate in September Investor Conferences Business Wire - 9/3/2020 8:30:00 AM
Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results Business Wire - 8/10/2020 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 7:03:14 AM
Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference Business Wire - 8/5/2020 8:30:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 7/30/2020 11:13:20 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/23/2020 8:37:07 AM
Millendo Therapeutics Provides Corporate and Pipeline Update Business Wire - 6/23/2020 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/23/2020 7:08:41 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/23/2020 7:08:01 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/23/2020 7:07:56 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/23/2020 7:07:31 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/23/2020 7:07:01 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/23/2020 7:06:31 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/23/2020 7:05:50 AM
Millendo Therapeutics Reports First Quarter 2020 Operating and Financial Results Business Wire - 5/8/2020 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2020 7:37:12 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/24/2020 3:02:38 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/24/2020 3:00:56 PM
DMOST Member Level  Friday, 09/06/19 12:51:26 AM
Re: None
Post # of 34 
Millendo Therapeutics to Participate in September Investor Conferences

Millendo Therapeutics, Inc. (MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that senior management will present company overviews and conduct one-on-one investor meetings at the following healthcare investor conferences:

Citi’s 14th Annual Biotech Conference
Date: Thursday, September 5, 2019 (one-on-one meetings only)
Location: Boston, MA

Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies
Date: Monday, September 23, 2019 (one-on-one meetings only)
Location: New York, NY

Ladenburg Thalmann 2019 Healthcare Conference
Date/Time: Tuesday, September 24, 2019 at 11:00 a.m. EDT
Location: New York, NY

A live webcast of the Ladenburg Thalmann presentation will be available on the Investors & Media section of Millendo’s website at http://investors.millendo.com. A replay of the webcast will be archived on Millendo’s website for 30 days following the presentation.

About Millendo Therapeutics, Inc.
Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome, nevanimibe for the treatment of classic congenital adrenal hyperplasia and MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit www.millendo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190829005139/en/


GO MLND

"PEACE"

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences